Tags Posts tagged with "marijuana legalization"

marijuana legalization

0 2131

Surprise! The Very First Marijuana Stock ETF Has Lost Investors Money

Surprise! The Very First Marijuana Stock ETF Has Lost Investors Money

The marijuana industry is growing like a weed, and marijuana stocks as a whole have been carried along in tow. Over the past year, a number of marijuana stocks have seen their valuations double, triple, or, in the case of AXIM Biotechnologies, rise by more than 3,600%. Both the 2016 Gallup poll and the more recent CBS News poll, both of which asked respondents whether they’d be in favor of legalizing recreational weed nationwide, have seen support for legalization climb to an all-time high (60% for Gallup and 61% for CBS News). Residents have voted to legalize recreational marijuana in eight states since November 2012, and over the past 21 years, 28 states have legalized the use of medical cannabis.

0 2037

Proposal Aims For Medical Marijuana Legalization In North Carolina

A recent proposal aims to legalize medical marijuana in North Carolina. The bill lays out the development of a medical marijuana supply system and aims to create a program administered by the UNC system called the North Carolina Cannabis Research Program. The program would conduct studies to determine the safety and efficacy of cannabis as medical treatment and then develop guidelines for the appropriate physician administration and patient use of medical cannabis.


Click Here Now To Read Full Article


Industrial Hemp Project At The University Of Minnesota

University of Minnesota students may do double-takes this summer if they spot what looks like marijuana plants growing on the agricultural testing fields at the St. Paul campus. However, the dark green foliage with jagged leaves will actually be industrial hemp, a close look-alike and cousin to marijuana that’s useless for getting high but potentially valuable for certain foods, cosmetics, and oil.


Click Here Now To Read Full Article


Texas One Step Closer To Decriminalizing Marijuana

Texas is one step closer to eradicating the criminal penalties associated with minor marijuana possession. The House Criminal Jurisprudence Committee recently put its seal of approval on a proposal (House Bill 81) that would allow police all over the state to simply slap those people caught in possession of up to an ounce of weed with a small fine instead of dragging them to jail. The state currently deems this offense a Class B misdemeanor, which carries the potential for marijuana offenders to serve up to six months behind bars.


Click Here Now To Read Full Article


1 3467

Cannabis shops and manufacturers have increasing concerns that the Trump Administration will enforce federal laws that restrict farming and selling the drug. This will reverse the president’s stance during his campaign and potentially overturn what has become a $7 billion industry. The worry was provoked by comments from White House spokesman Sean Spicer recently that the government would most likely boost its enforcement of drug laws.

Attorney General Jeff Sessions stated that he is “dubious” about the benefits of marijuana. He said, “Marijuana is against federal law, and that applies in states where they may have repealed their own anti-marijuana laws. So yes, we will enforce law in an appropriate way nationwide. It’s not possible for the federal government, of course, to take over everything the local police used to do in a state that’s legalized it. And I’m not in favor of legalization of marijuana. I think it’s a more dangerous drug than a lot of people realize.”

The comments have sparked worry with Chuck Smith, co-founder of Dixie Brands, a Denver-based company that manufactures topicals and edibles infused with THC, the active ingredient in cannabis. He founded the company in 2010 and now employs more than 100 people across Arizona, Colorado, California, and Nevada. Smith stated, “My concern right now for both the company and industry is just uncertainty. It’s hard to build an industry or a company when you don’t have clarity.”

The administration’s statements affected shares of Innovative Industrial Properties, which invests in cannabis-growing facilities and is one of the few publicly traded cannabis companies. Its stock price plummeted on the day of Spicer’s press conference and are down more than 13% since then. However, two other marijuana stocks, GW Pharmaceuticals and Cara Therapeutics, seem to have not been affected by the news.

Eight states now allow the use of cannabis recreationally, while more than two dozen states have legalized it for medical purposes. Twenty-one states have decriminalized cannabis. A recent Quinnipiac Poll found 71% of voters think the government should not restrict federal drug laws in states where marijuana is legal. Increasing acceptance has led to an jump in the market for cannabis in North America, with sales rising 34% to nearly $7 billion in 2016, according to Arcview Market Research. By 2021, the industry is likely to climb close to $22 billion.

Companies like Dixie Brands are charging that hike. The privately held company would not disclose current numbers, but in 2014 it was valued at $40 million. Smith said, “It’s hard for us to kind of go backwards. President Trump said he was going to allow this to be a state’s rights issue. We took him at his word.” Trump has sent mixed messages on cannabis. In the 1990s, he called for legalizing all drugs. On the campaign trail, he reiterated his support for medical cannabis and his deference to states to pass their own laws regulating the drug.

0 3201

A new proposal before legislators in Salem is arranged to protect people who purchase cannabis in Oregon. It’s considered emergency legislation, which means that if passed, it would immediately take effect. This proposal comes after comments from the federal government about pushing back on the six states that have legalized cannabis. Back on February 24, 2017, White House press secretary Sean Spicer said, “I do believe you will see greater enforcement of it.”

When asked about medical cannabis, Spicer stated, “that is very different than recreational use, which is something the Department of Justice, I think, will be further looking into.” Currently, when you buy marijuana in Oregon, the business records your identification information to ensure you’re not purchasing more than the legal amount per day. The CEO of Cannabliss & Co. in Portland, Matt Price, says the need for minimal identification information is to ensure buyers are staying within the legal limit.

Price stated, “If I have to purge the system and come up with some crazy way to track individuals it would be easy for people to abuse those powers.” Senate Bill 863 does two things. First, cannabis dispensaries or retailers wouldn’t be able to keep anyone’s information for more than four days. Second, it would make it illegal for the retailer or dispensary to give anyone’s information to anyone else. On the bottom of the bill’s summary it states the emergency act is “necessary for the immediate preservation of the public peace, health and safety.”

Price stated, “There is a lot of fear in a new administration I think these guys are going to be a little more stringent but I don’t think they are going to be messing with any licensed legal state business.” Senator Floyd Prozanski is one of the key supporters of the bill he says the goal is to ensure voters got what they were expecting when they passed Measure 91. He says the hope would be to get the marijuana industry to be more like the alcohol industry, meaning marijuana stores check age but don’t keep consumers’ personal information.

1 16739
Jeff_Sessions_Legal_Marijuana

“Wait did I read that correctly?” you’re probably asking yourself, right? Mr. Sessions has seemingly been the thorn in the side of the legal marijuana movement and he’s been a topic of great debate for days now. But there may be some shining light ahead to put a bit more ease to those looking at this industry and in their favor. Yes, worries about this “great shift” in federal enforcement in states where recreational legalization has been granted may be able to breathe a little easier right now.

There’s been an immense amount of angst and paranoia with regard to what some have understood as a government crackdown on recreational use. U.S. Attorney General Jeff Sessions has had private discussions with a few Republican senators saying that he doesn’t plan to stray away from the Obama-placed policy of granting states the ability to enact their own marijuana laws for their residents.

Sessions has been a strong force to be reckoned with after he ordered a review of the “hands-off” policy that President Barack Obama previously had. But apparently Mr. Sessions has had a bit of a change of heart and in private conversations, has assured senators before he was confirmed that he didn’t have too much consideration about drastically changing the enforcement laws; even though he’s not a fan of the drug’s use.

Here are a few quotes from these informed senators:

“Nothing at this point has changed,” said Sen. Cory Gardner (R-Colo.)

“He told me he would have some respect for states’ right on these things. And so I’ll be very unhappy if the federal government decides to go into Colorado and Washington and all of these places. And that’s not the [what] my interpretation of my conversation with him was. That this wasn’t his intention.”

-Sen. Rand Paul (R-Ky)

“We respectfully request that you uphold DOJ’s existing policy regarding states that have implemented strong and effective regulations for recreational use. It is critical that states continue to implement these laws.”

-Sens. Elizabeth Warren (D-Mass.) & Lisa Murkowski (R-Alaska)

“Do they really respect states’ rights? Then you should respect all of them, not just pick and choose the ones that you want to support or not. Many states have gone not only the path of Nevada of recreational marijuana but medical marijuana. How can you pick or choose one or another?”

-Sen Catherine Cortez Masto (D-Nevada)

A group of bipartisan senators also had submitted a letter on Thursday that pushed for Sessions to keep the Obama-era policy intact in order to let states decide on how to implement recreational marijuana laws. Sen. Warren and Sen. Murkowski lead the effort; both of who are from states who’s already put legalized marijuana laws in place.

To date, 8 states and Washington, D.C. have laws in place that legalize marijuana for recreational use. Most senators who signed on the letter are from those states with Murkowski being the only Republican. The others include:

Sen. Patty Murray of Washington
Sen. Ron Wyden of Oregon
Sen. Jeff Merkley of Oregon
Sen. Maria Cantwell of Washington
Sen. Ed Markey of Massachusetts
Sen. Brian Schatz of Hawaii
Sen. Catherine Cortez Masto of Nevada
Sen. Cory Booker of New Jersey
Sen. Michael Bennet of Colorado

The concern isn’t just among senators from those states but is an issue among many conservatives who are nervous about the GOP being selective about allowing the rights of states to supersede federal law.

“We’re concerned about some of the language that we’re hearing. And I think that conservatives who are for states’ rights ought to believe in states’ rights. I’m going to continue to advocate that the states should be left alone,” Paul said.

Sen. Gardner was even more direct with the opinion on Sessions’ comments, “He was talking about if there’s cartels involved in illegal operations, they’re going to crack down on that. That’s what everybody’s saying. I still haven’t heard Jeff Sessions say that. We obviously want to make sure we’re clear on what they’ve said.”

Despite the shake-up that Sessions almost single-handedly ignited with his comments about “not being a fan of expanded use of marijuana,” or how despite him being open to states passing laws that they choose, he made it a point to say, “it does remain a violation of federal law to distribute marijuana throughout any place in the United States, whether a state legalizes it or not,” senators like Murkowski seem unshaken. In fact Murkowski said that she wasn’t alarmed and is simply monitoring the DOJ closely, “It’s probably a little premature to try to predict what may or may not be coming out of the administration on this, so I think we just need to sit back and see.”

4 10532

By Jason Spatafora @WolfofWeedSt

“I fear the Greeks, even those bearing gifts.”- Virgil

The DEA’s recent cannabis research expansion is a Harry Houdini inspired smoke show of misdirection all to set up the next trick; there I said it. While some view it as a positive first step, I tend to think it served a very deliberate function. Optically it played directly into expected vitriolic fallout from advocates, activists and media touts, all of which lined up to ignite their “DEA should reschedule cannabis” torches. In a “perfect world” scenario these people aren’t wrong, cannabis isn’t Heroin’s equal & 1+1=2, but just as fire cannot exist in a vacuum, neither can a rational cannabis debate. And while everyone on the side of reason is shouting in unison about rescheduling they failed to see that they might have just had their pockets picked. DEA’s policy statement that everyone seemed to ignore there are 33 words that have the potential to create the legal framework for the monopolization of Cannabis by means of an exclusionary application process.

Prologue – August 10th, 2016

Russ Baer, a staff coordinator for the Drug Enforcement Administration (DEA) media affairs wing gave a response to Steven Nelson of USNEWS.com via email. Nelson later shared a screen grab of the email via tweet. The statement made to him from this Drug Enforcement Administration staff coordinator read:

“Tomorrow morning (August 11th, 2016) the Drug Enforcement Administration will be making some important announcement regarding Marijuana related topics that will be published in the Federal Register. Because of your interest and/or prior engagement with the DEA on this subject, the DEA office of National Media Affairs is reaching out to you regarding these anticipated announcements.”

Over the next 24 hours social media was a blaze, with many people within the industry uncovering the fact that Rescheduling wouldn’t happen and that the DEA response would have to do with research. As expected, the incendiary scheduling of cannabis debate raged on into the following day.

August 11th, 2016

As expected, the Drug Enforcement Administration disappointed the advocates and activists of medical marijuana by not removing or rescheduling marijuana from its class 1 controlled substance status. Yet the DEA, in all of its benevolence, offered a consolation prize of sorts, by “deciding” to expand the study of Medical Marijuana for researchers, Universities & drug companies outside of the confines of a single federally legal facility. The facility, to refresh your memory is located at the University of Mississippi, (ranked 164th in Bio Sciences) and had up to this point been the sole research monopoly on legally grown marijuana, courtesy of the NIDA (National Institute on Drug Abuse).

DEA’s Misdirection Strategy

Over the next few days it seemed that every headline following the DEA’s deliberation was about the archaic rescheduling system & how cannabis is safer statistically than opiates that are schedule 2. Some media outlets went as far as to paint a “glass half full” picture. The LA Times for example did a piece titled “DEA ends its monopoly on marijuana growing for medical research.” The social reaction from cannabis enthusiasts, advocates and potrepreneurs from Main Street to Wall Street was as expected with everyone chiming in on social media to wag their fingers at the DEA. Representative Barbara Lee, a congresswoman from Oakland California stating via tweet “Politicians aren’t doctors or scientists. Marijuana research prohibitions are outdated, unscientific, & dangerous for those who need #MMJ.” As expected the rhetoric from the cannabis side was “The DEA is bad, the War on Drugs is a complete failure, Big Pharma is to blame,” so on and so forth.

IMG_8473

The people aren’t wrong on many of these points. The War in Drugs is a failure when considering addiction has been plateauing since its 1970 inception and US drug control spending is up 2000%, which to date stands at $1.5 trillion dollars. We can go on and on as to where that money went, what industries it created (prison industrial complex), the people it disproportionately targeted (minorities), but that’s a whole other article or book for that matter. Big Pharma however does have its trillion dollars hands in this story, but more on that later as I’ve digressed.

Not to go back and pick on the LA Times click-bate headline of “DEA ends its monopoly on marijuana growing for medical research,” but did it really end the monopoly? Let’s evaluate the idea. Yes, a monopoly is defined as “the exclusive possession or control of the supply or trade in a commodity or service.” The University of Mississippi was in fact in exclusive possession of the NIDA edict to legally grow marijuana and study it. On the surface the Monopoly has ended, but the reality is that we are just switching out the term Monopoly for an Oligarchy. Is an oligarchy any different than a monopoly in the sense that it’s just a smaller group carving out the biggest slices for themselves, eliminating competition by means of out maneuvering or outspending their opponent in an effort to influence policy such as this? Consider that the biggest lobby against the cannabis Industry is the pharmaceutical industry, yet they’re simultaneously studying cannabis for the purpose of synthesizing its many chemical compounds to create their high margin drugs.

Currently, their high margin bread and butter are the opioids for pain management such as OxyContin, Percocet and their generic versions of each. The drug companies are experts at isolating molecules from nature to create drugs that cost pennies to manufactures. In a zero sum game, cannabis is a direct threat to pharma companies, by snatching billions in profit and simultaneously causing billions in losses. Anti-cannabis lobbies would also be at risk as the pharmaceutical giants that feed them down on K Street would lose out on easy paydays. These anti-Marijuana lobbyists provide a micro look at the systemic problems within American politics illustrating how/why elected officials in Congress consistently vote against the interests of their collective constituency and bring forth carefully crafted bills or amendments like this one.

On the DEA’s policy statement and legal considerations section, under, legal applicable considerations it states.

“Second, as with any application submitted pursuant to section 823(a), in determining whether the proposed registrationwould be consistent with the public interest, among the factorsto be considered are whether the applicant has previous experience handling controlled substances in a lawful manner and whether the applicant has engaged in illegal activity involving controlled substances. In this context, illegal activity includes any activity in violation of the CSA (regardless of whether such activity is permissible under State law) as well as activity in violation of State or local law. While past illegal conduct involving controlled substances does not automatically disqualify an applicant, it may weigh heavily against granting the registration.”

Translation, grow marijuana even in a state where it’s legal and you are going to have a hard time becoming a manufacturer or researcher for the DEA’s new policy, thus excluding tier one cultivators in practice and likely creating a perpetual home for cannabis on the scheduling list. Prohibition’s end could very well be right around the corner, but the fear is in the form of legal medical marijuana at a Walgreens near you. I asked the DEA’s Russ Baer directly if the inserted language above in bold would be a non-starter for current cultivators wanting to become manufacturers as they are in clear Violation of CSA? In a written statement to Marijuana Stocks the DEA’s official response was:

“DEA is serious about facilitating marijuana research and that there is a lawful pathway for doing so. This DEA decision will facilitate increased research involving marijuana, within the framework of the law and U.S. treaty obligations, to enhance the drug’s supply available to researchers. The goal of this historic and monumental policy shift is to increase the amount and variety of marijuana available to researchers and make it easier for researchers to obtain marijuana as compared to current system under which marijuana must be obtained from NIDA. Growers must become registered with DEA, following the submission of an application, which DEA will evaluate in accordance with the CSA. Registered growers will need to comply with all CSA regulatory requirements, such as quotas, record keeping, order forms, and maintenance of control against diversion. Marijuana produced under this proposal may only be supplied to DEA-registered manufacturers and researchers, and only for purposes authorized by the CSA.

All potential new drugs, including drug products made from marijuana, are subject to the rigors of the drug approval process mandated by the Federal Food, Drug and Cosmetic Act (FDCA). This drug approval process requires that before a new drug is allowed to enter the U.S. market, it must be demonstrated through sound clinical trials to be both safe and effective for its intended uses,” stated Russ Baer of the Drug Enforcement Agency.

When asked if the inserted language also creates an unfair advantage for Pharma companies the response from the Drug Enforcement Administration circled back to the CSA (Controlled Substance Act) stating that the “DEA has adopted a new policy, consistent with the CSA and U.S. treaty obligations, under which additional entities may become registered with DEA to grow and distribute marijuana for research purposes. DEA will evaluate each application it receives to determine whether adding such applicant to the list of registered growers is necessary to provide an adequate and uninterrupted supply of marijuana to researchers in the U.S. In addition, applicants must demonstrate their ability to safely secure the drugs to prevent diversion, while abiding by the approved research protocol.”

The Controlled Substance Act

Everything points back to the Controlled Substance Act, a bill that was introduced into the Congress by Harley Staggers and took less than 6 weeks to get passed by the Senate and signed into law by President Richard M. Nixon. The signing of this document not only created the “War on Drugs,” but put an enforcement agency (DEA) in charge of Cannabis scheduling, circumventing the FDA in a move that creates an inter-agency firewall of sorts. The DEA’s position on why the FDA, who already regulates pharmaceutical drugs, isn’t in charge of marijuana rescheduling was point blank, “The Controlled Substances Act provides a mechanism for substances to be controlled (added to or transferred between schedules) or decontrolled (removed from control). The CSA provides roles for DEA and the FDA. Proceedings to add, delete, or change the schedule of a drug or other substance may be initiated by DEA, HHS, or by petition from any interested party. Once initiated, the process involves a deliberate and collaborative interagency exchange.”

IMG_8472

In Laymen’s terms CSA effectively says “DEA you’re in charge of this, FDA you’re in charge of that.” Unfortunately, Marijuana will never be completely removed from the scheduling list unless there is a major political overhaul in every branch of government, if and only if elected officials stop letting lobbies pour honey in their ears and money into campaigns. The reality from my perspective is that the DEA is a scapegoat, the perfect Boogey Man, simply because their job is to follow orders. They are soldiers in a sense, adhering to the guidelines of the Controlled Substance Act (CSA), a legal document crafted by a congress, molded in the image of benefactors, used to fuel a fake war and create cottage industries.

The DEA knows marijuana is safer than Oxy and that’s not speculation that’s a direct quote. They don’t want to go after the mother transporting medication to her sick child because they’re suffering from seizures. They want the dangerous individuals like El Chapo or the pill mills slinging Oxy off the streets. They have no interest in going after all cultivators following state law to the letter. Are there exceptions, of course! Does it make these comments directly from them any less true? No.
DEA’s direct position on which drug is more dangerous from a consumption standpoint as it relates to Cannabis vs OxyContin? “There were more than 47,000 drug overdose deaths in 2014, or approximately 129 per day, more than half (61 percent) of which involved either a prescription opioid or heroin. Marijuana meets the statuary criteria of a Scheduled I controlled substance, and has been determined to have a high abuse potential with no currently accepted medical use. Schedule I includes some substances that are exceptionally dangerous (including heroin and LSD) and some that are less dangerous (including marijuana, which is less dangerous than some substances in other schedules).” When asked point blank, what’s more dangerous Oxy or Marijuana DEA says “Oxy.”

Robert Capecchi, Director of Federal Lobbying at the Marijuana Policy views medical marijuana legalization as a means to an opioid end as well as fiscal no brainer with far reaching benefits.

“Ending marijuana prohibition will allow licensed businesses to cultivate, distribute, and sell marijuana to adults. Unlike the criminal market, a legal and regulated market means products are pure, tested and labeled, sales are taxed, and business disputes are resolved in the courts, not with violence. Additionally, there is promising evidence to suggest that legal access to medical marijuana reduces the rates of opioid overdoses and the reliance on prescription pain killers.”

Foregone Conclusion?

Prohibition’s end could very well be right around the corner, but would we want it in the form of legal medical marijuana at a Walgreens near you? August 11th’s ruling was either one of many dominos in the quest for the monopolization of cannabis or just a pessimistic idea based off of history repeating itself. Regardless of which reality we are presently in, it doesn’t hurt to try and connect the dots, but if I can leave you with one last thing it’s the number 6630507. In case you’re wondering that’s the United States patent # they filed for cannabis in 2003 citing “multiple therapeutic uses.” I can only postulate why they did that….

Regards,

Jason Spatafora

Drug War

    0 1332

    The volume of cannabis stocks listed on the Nasdaq have spiked ahead of the election with some stocks rising as much as 12% on Monday as voters decide tomorrow whether five states will allow recreational use of marijuana while four other states could approve medical use.

    Interest in cannabis-related stocks has risen from micro cap to Nasdaq-listed equities, said Jason Spatafora, co-founder of Marijuanastocks.com and a Miami-based trader and investor known as @WolfofWeedST on Twitter. The market is predicting that voters in California and Nevada will approve legislation for recreational use and anticipates that Florida will legalize medical use.

    “Should more states adopt laws to legalize either recreational or medicine use of marijuana, we can see a continued run going into the new year,” he said.

    -Continue Reading, Here-

    0 2517

    Arcturus Growthstar Technologies Inc.: CEO Update to Shareholders

     Arcturus Growthstar Technologies Inc. (the “Company” or “Arcturus”) (CSE:AGS) (OTC Pink: AGSTF) is pleased to provide the following update to its current and prospective Shareholders regarding the Company’s recent activities relative to Arcturus’ current lines of agricultural technology, cannabis based media and app platforms and its expansion into urban farming markets. This update also lays out Arcturus’ plans for the immediate future, including the Company’s first Shareholder Conference Call.

    Arcturus is a British Columbia company focused on developing and marketing products in the consumer LED industry and in the Controlled Environment Agriculture (“CEA”) industry through its online sales channels and web presence relative to its Scorpion LED & COB grow lights. Recently, Mr. Rob Huston, the head of the Company’s LED division, won 1st place for the “Indica – Private Grower” category at Bio Cup Canada, the largest cannabis cup to ever take place in Canada by using the Company’s Scorpion COB grow lights with off the shelf seeds. Five plants were grown legally using an MMAR patient license in a 4’x8′ space, using 1500 watt total, consisting of 1 Scorpion 9x 525 watt and 3 Scorpion 5x 325 watt each. Mr. Huston’s five plants were harvested at eight weeks and resulted in a 1.35-lb harvest.

    Arcturus has had much success in the LED space, even prior to Mr. Huston’s award, putting itself in a very good position ahead of medical marijuana legalization in Canada. Now that the Trudeau administration has signaled its plan for a complete legalized cannabis market, Arcturus is using its current lines of LED and CEA technologies to penetrate the market and aid in the growing number of licensed producers (LP’s) building out their facilities.

    With an eye beyond simply sales, the Company contracted with Mr. John Sweeney, formerly the vice president of operations for Tilray, one of Canada’s biggest privately licensed cannabis producers owned by Privateer Holdings. Mr. Sweeney will spearhead the Company’s professional consulting services in the area of “current Good Manufacturing practice” (cGMP), which provides for systems that assure proper design, monitoring, and control of manufacturing processes and facilities in support of mandates on the horizon.

    The Company also engaged the services of CBO Financial, Inc. as its financial advisor with respect to New Market Tax Credits (NMTC) for a vertical farm project. The NMTC program is a $65 billion federal program designed to incentivize private investment in low-income communities. NMTCs are provided to financial institutions in exchange for equity investments that eligible businesses can use to subsidize project development costs. The NMTC program provides 20% to 25% of a project’s cost in very flexible financing for projects located in low-income communities. CBO Financial helps driven organizations, such as Arcturus, to finance facilities that will provide goods and services that benefit populations in need and revitalize communities. Arcturus’ partnership with CBO Financial is both shareholder and capital structure friendly in the sense that the draw of capital is non-dilutive in nature. Arcturus and CBO Financial are currently developing one vertical farming project together, but plan to work together on many more projects in the future.

    On October 4, 2016, the Company closed on its transaction to acquire a large portfolio of revenue generating Apps and source code (the “App Portfolio”). This all-stock acquisition brings on a seasoned team of app developers, which instantly expands the Company’s tech portfolio and positions Arcturus for rapid rollout of a suite of cannabis centric apps.  “As more and more states legalize the use of Cannabis we believe that more and more technology will be needed to manage the growth of consumers with apps being the centerpiece; be it delivery, discovery, customer acquisition, or eventually payment services,” says Mikael Hovhannisyan the app manager.

    The App Portfolio is currently producing revenue and is a consistent source of monthly income, as the App Portfolio’s trailing 12-month EBITDA was USD $139,000 or CDN $183,000. Subsequent to closing on this transaction, the Company’s new app team established a new mobile gaming division with the intent to put out 420 themed games, which will generate revenue through In App Purchases (IAP) as well as through ad impressions.

    1 2486

    CHEYENNE, Wyo., Sept. 26, 2016 /PRNewswire/ — FBEC Worldwide, Inc. (FBEC) a lifestyle brand company with a focus on Healthy Hemp™ & CBD infused consumer products, is pleased to announce that Amazon.com, Inc. (AMZN) has received FBEC’s WolfShot™ brand of Healthy Hemp™ Energy Shots & is now available for sale on Amazon.com. Wolfshot™ can be purchased here https://www.amazon.com/gp/product/B01IC71UGA.

    This announcement comes after the company announced on September 14, 2016 that it had received a follow up purchase order after a successful test run of WolfShot™ via the Amazon Vendor Express Program. Amazon’s Vendor Express Program allows companies like FBEC Worldwide, Inc. to sell their products directly to Amazon.com, Inc. (AMZN). Amazon takes care of the shipping, promoting & customer service.

    CEO Jeff Greene stated, “Current & potential customers can once again visit Amazon.com & purchase FBEC’s WolfShot™ brand of Healthy Hemp™ Energy Shots. After our previous successful test run with Amazon Vendor Express we look forward to a continued positive reception of our products.”

    About FBEC Worldwide, Inc.

    FBEC Worldwide, Inc. is a lifestyle Brand Company with a focus on Healthy Hemp™ & CBD infused consumer products, both domestic and abroad. We are committed to increasing our market size and scope through the optics of creative marketing and most importantly customer satisfaction. Our growth strategies focus on a number of major initiatives, including unique branding opportunities that will be targeted at key demographic groups and to develop strong community and distributor relationships.

    FBEC Worldwide is currently developing and building Healthy Hemp™ & CBD infused consumer products, focused on strong rates of growth within key fundamental consumer groups. Our company is dedicated to becoming the lead developer of name brand hemp & CBD infused consumer products.

    Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The Company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.

    Investor Relations Contact:

    Joe Sirianni
    MIDAM Ventures LLC
    (305) 707-7018
    jsirianni@MidamIr.com
    www.MIDAMIr.com

    An affiliate of MAPH Enterprises, LLC MarijuanaStocks.com | WolfofWeedStreet.com was paid an advertising fee of $60,000 cash & 60 Million Restricted Common shares by FBEC Worldwide Inc. (FBEC) for visual sponsorship of MarijuanaStocks.com | WolfofWeedStreet.com and for visual placement FBEC Worldwide Inc. (FBEC) within written materials. FOR A DURATION OF 5 YEARS BEGINNING JUNE 2015 ending JUNE 2020

    PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

    0 2772

    Ubiquitech Software Announces Name Change to “HempLife Today” Plus Releases Overview of Exciting Plans to Increase Revenues and Continue Company Growth

    DENVER, CO–(Marketwired – Sep 20, 2016) – Ubiquitech Software Corp. ( OTC PINK : UBQU ), CEO and the management of (UBQU) want all shareholders, and the general public, to have an update and overview on the exciting plans the company is implementing in order to continue the upward growth of revenues and the expansion of the CannazALL™ CBD brand.

    The company currently has plans for the following over the next 30 – 120 days, and into 2017, and will be very active in keeping shareholders and the general public updated on a weekly basis…

    Official Name and symbol change to HempLife Today™: Pending the legal requirement filings the company will be known as HempLife Today™, with new symbol (To replace UBQU), also pending. The company believes that the already extensive reach of the HempLife Today™ name, the millions spent on branding, and the ability to leverage this brand into a worldwide powerhouse is the best choice to expand the CannazALL™ CBD product line to a larger market share, and offers greater flexibility and profit potential as the Hemp industry continues to grow.

    New HempLife Today™ logo: Update and freshen the HempLife Today™ logo to add a stronger look to our brand.

    New products: The Company has plans to announce 2-4 new CBD products in 2016.

    New and improved packaging: To increase customer satisfaction, increase public awareness, and also allow for greater retail sales opportunities.

    New proprietary CBD blend: The company is currently developing a new proprietary blend of additional hemp plant products to its CannazALL™ CBD formulas. Making CannazALL™ even more a one-of-a-kind and unique CBD health product, that can only be found in the CannazALL™ brand.

    Introduction of Direct Mail to advertising campaigns. The company is introducing direct mail campaigns to its buyers and subscriber lists, and will be expanding this advertising campaign to larger databases of potential new customers

    CBD GelCap Free Sample: As announced on 9.16.2016…The Company will be BETA testing this offer in October with plans to roll out in November and December. Current data show the Company could add over 50,000- 100,000 new customers annually through this marketing platform.

    Additional Affiliate companies: The Company is currently working with “Content Specific” Sites that can act as Affiliate sellers of CannazALL™ CBD products. Company announced PotGuide.com and ColoradoPotGuide.com were added to its Affiliates earlier this month.

    New CannazALL™ YouTube channel: The Company plans to create a new YouTube channel that will offer instructions and details on CannazALL™ products, dosing, and general information.

    New company, product, and investor video presentations: To be added to the HempLife Today™ Websites and landing pages.

    Improved Delivery: It is the Company goal to ship same day on orders placed before 9Am (MT), and next day on orders placed after 9AM. Company data show that fast shipping results in more frequent, and larger, repeat orders.

    International sales: Expanded delivery into other CBD friendly countries (To be announced in future Press Releases)

    “Going into our third year we are solidifying everything necessary to succeed and be the leader” Said Tim Zorn of HempLife Today™ “Our products are the best they can be, the demand for our products is growing, and our name, brand, and production and delivery systems, are all in place. We are ready to spread the HempLife Today name, and the Cannazall CBD brand, to a bigger and bigger audience”

    “If people think that 2016 has been good so far, just watch what we achieve moving forward” James Ballas of HempLife Today™ “With our new name and symbol change we are ready to expand and grow this company faster than ever before. We feel like a sprinter that’s about to reach full speed, and once we do, there will be no catching us”

    The company is aware that shareholders, and the public, are eager to learn about, and to share, all of the new and exciting plans the company is implementing. Because of this the Company will keep shareholders completely informed on a weekly, and sometimes daily, basis to show the progress of the stated goals in this press release.

    About Ubiquitech (HempLife Today™)
    Ubiquitech Software Corp, through its subsidiaries is a dynamic multi-media, multi-faceted corporation utilizing state-of-the-art global internet marketing, Direct Response (DRTV) Television, Radio, and traditional marketing, to drive traffic to the new and emerging multi-billion dollar industries like its subsidiary HempLifeToday.com™

    HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; It’s popular CBD Tinctures, Oils, GelCaps, CBD Powder, Skin Salve, Wax Crumble, and e-liquid, all offered @ www.HempLifeToday.com

    This press release contains forward-looking statements. Words such as “expects”, “intends”, “believes”, and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company’s filings with the OTC Markets Group. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward- looking statements in order to reflect events or circumstances that may arise after the date of this release.

    Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

    We are your #1 source for all things Marijuana Stocks, Subscribe Below!

    Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
    Ad Placements